Octagon Research Solutions, Inc., has released version 4.0 of its global submission document authoring template suite, StartingPoint.
StartingPoint 4.0 is designed to offer standardized templates and formatting functionality to those authoring the various components of a CTD (Common Technical Document) or eCTD (electronic Common Technical Document) regulatory submission. StartingPoint 4.0 offers new content templates, improved functionality and compliance with Windows 7.
New functionality includes:
* Enhanced error identification and management o
- Expanded list of errors highlighted by the Document Validation tool
- A new ‘Report Generation’ mode that enables the user to generate a comprehensive report of all errors found in the document.
- The addition of a ‘Replace All’ feature allowing replacement of all instances of erroneous style with one button push.
* Enhanced toolbar automation that addresses common challenges with table and footnote formatting
* Automated ‘Replace Styles’ functionality that allows the user to map each existing style in a document to a specified StartingPoint style.
* New and enhanced content templates reflecting recent changes in regulatory guidance including:
- 1.16 Proposed Risk Evaluation and Mitigation Strategies (REMS)
-1.16 Risk Evaluation and Mitigation Strategies (REMS) Supporting Document
-1.6.1 Meeting Request
-1.6.2 Pre-NDA Meeting Background Materials
“The Risk Evaluation and Mitigation Strategies (REMS) content template was added to this version of StartingPoint as a result of our agency interactions and is based on just released guidance from the FDA. We are seeing an increased emphasis on the REMS and felt it appropriate to include the content template to assist our clients in developing a framework for this critical document," stated John Lawrie, vice president, Process Consulting.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.